The Medicines Company's cangrelor leads trio of CHMP opinions
This article was originally published in Scrip
Executive Summary
The Medicines Company is celebrating receiving three positive opinions from the EU's CHMP at its latest meeting this week, including for its antiplatelet agent Kengrexal (cangrelor), and its sealant powder Raplixa. Its antibiotic Orbactiv (oritavancin) was also one of two such products given marketing go-ahead by the committee (see scripintelligence.com, 23 January 2015).